Meta's selloff deepens while the Street holds firm

Meta Platforms fell harder than almost any name in its peer group this week, dropping 10.7% to $620.19 while the median decline among its closest correlated peers was 5.3%, and that gap is the sharpest fact on the tape right now.

Among peers, NXDR lost 5.9% and ZH shed 5.7%, both meaningful but well inside Meta's drawdown. Japanese peers tracked closer to Meta's magnitude: 323A fell 8.9% and 7047 dropped 6.6%, suggesting some global selling pressure. But Meta's decline is distinctly steeper, concentrated in a stock that has now lost 17.5% over the past month from what was still a $777 handle in early October. The week's move follows a 6.5% drop after the October 21 earnings release, which was already more than double the peer median that day. Shares are now trading nearly $230 below the consensus analyst mean target of $848.

Short interest itself is not the story. At 1.3% of free float, the absolute level is low enough to be almost structurally irrelevant. The week-on-week change is more notable: short interest dropped roughly 14% versus the prior week, a move that ORTEX flags as 2.5 standard deviations below the company's typical weekly change over the past year. Much of that unwind preceded the earnings release, concentrated around October 26 in the session after Meta's $95 billion capital raise was announced. Borrow costs ticked up to 0.40% from 0.19% the prior day, but that remains negligible in absolute terms. Availability is effectively unlimited, with no pressure from the lending market in either direction. Options positioning has eased: the put/call ratio has slipped back to 0.49, fractionally below its 20-day average and well inside the year's range of 0.41 to 0.70. The hedging premium that built into the print has largely unwound.

The analyst community has not moved. Ten firms raised targets on October 22, the day after the earnings selloff, and none cut ratings. The direction of travel is uniformly bullish: UBS held Buy with a $892 target, Citigroup held Buy at $905, Mizuho lifted its Outperform target to $950 from $750, and Barclays moved its Overweight target to $880 from $780. Wells Fargo was the lone outlier, trimming by $5 to $995 while keeping Overweight. The valuation picture has compressed alongside the price. The PE multiple has pulled back nearly 3 points over the past month to 18.1x, and price-to-book has dropped roughly 0.7 points to 4.4x, both reflecting the severity of the de-rating. The ORTEX short score sits at 28.6, low and declining gently, while the EPS surprise factor rank at 41 and the forward earnings growth rank at 27 flag some softening in the fundamental momentum picture.

The bear case is concrete. Free cash flow turned negative in Q3. Management guided 2026 operating expenses to $175 billion to $179 billion, which implies roughly 50% year-on-year cost growth at the midpoint. The planned Class C share structure from January 2027 and the $95 billion capital raise raise dilution questions that the analyst targets do not fully price in. The bull case rests on 3.64 billion daily active people, 26% Q3 revenue growth to $64.6 billion, and a core advertising engine that AI is making more effective. Muse drew over 10 million setups in six weeks, with roughly 25% daily usage and average transaction values above $200. Capital Research added 9.4 million shares in the quarter to September, the largest addition among top holders, while BlackRock added 4.6 million and State Street 3.5 million, all in the same period. Those flows reflect institutional conviction that the cost cycle is temporary.

What matters next is whether the October 28 Q3 results, released today after the close, shift the capex narrative the $95 billion raise was designed to answer. The last two earnings prints each produced single-day declines of more than 6%; the question is whether the capital-raise structure changes how investors read the spending guidance, or whether the dilution concern simply replaces the liquidity concern as the next overhang.